Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 22, Issue 1, 2002, Pages 60-66

  Dittrich, Elisabeth ^a   Schillinger, Martin ^a   Sunder Plassmann, Gere ^a   Hörl, Walter H ^a   Vychytil, Andreas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Erythropoietin; Ferritin; Iron deficiency; Renal anemia; Transferrin saturation

Indexed keywords

ALUMINUM; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ARTICLE; CALCULATION; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMATOCRIT; HUMAN; HYPERFERRITINEMIA; HYPERPARATHYROIDISM; INFECTION; IRON DEFICIENCY; MALE; PERITONEAL DIALYSIS; PHAGOCYTE; PRIORITY JOURNAL; TRANSFERRIN BLOOD LEVEL;

EID: 0036226203     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080202200110     Document Type: Article

References (25)

1. Iron status in patients receiving erythropoietin for dialysis-associated anemia
2. Iron management in end-stage renal disease
3. Importance of iron supply for erythropoietin therapy
4. Intravenous ferric saccharate as an iron supplementation in dialysis patients
5. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: A single center comparative study
6. Indices of iron status in continuous ambulatory peritoneal dialysis patients
7. Iron status and iron supplementation in peritoneal dialysis patients
8. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients
9. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients
10. Intravenous iron for CAPD populations: Proactive or reactive strategies?
11. Parenteral iron use in the management of anemia in end-stage renal disease patients
12. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration
13. European Best Practice Guidelines 6-8: Assessing and optimizing iron stores
14. Serum transferrin receptor and transferrin receptor/log ferritin index predicting response to erythropoietin and intravenous iron therapy in hemodialysis patients
15. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency
16. Bleomycin detectable free iron (BDI) is present in patients on intravenous (IV) iron therapy
17. Incidence of peritonitis in chronic peritoneal dialysis patients infused with intravenous iron dextran
18. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia
19. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis
20. Adequacy of dialysis and differences in hematocrit among dialysis facilities
21. Relationship between anemia and adequacy of continuous ambulatory peritoneal dialysis
22. Erythropoietin in chronic renal failure
23. Total iron-binding capacity - Estimated transferrin correlates with the nutritional Subjective Global Assessment in hemodialysis patients
24. Erythropoietin (EPO) requirements remain high in EPO resistant patients after iron repletion
25. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously